Shuttle Pharmaceuticals Holdings, Inc.

Listed Company

SHPHCIK 0001757499NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-11.70M

Total Assets

$10.48M

Equity

$2.25M

Shares Out

5.59M

Op. Cash Flow

$-9.48M

Business

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company developing proprietary small molecule therapies to sensitize cancers to radiation and modulate anti-tumor immune responses. Its main products and candidates include Ropidoxuridine (IPdR) as an oral radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225, SP-1-303) and diagnostic assets (PC-RAD test, PSMA-B ligand). The company operates through drug development and diagnostics subsidiaries, research collaborations and third-party manufacturing arrangements. It conducts clinical development and distribution primarily in the U.S. via academic partnerships, CROs and clinical trial sites.

Summary from filing dated 2025-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	—	—	—	—	—
Research and development	4	4	4	1	1
General and administrative	6	1	1	538,796	36,500
Legal and professional	2	3	1	866,770	684,684
Total operating expenses	12	8	6	3	2
Net loss from operations	−12	−8	−6	−3	−2
Interest income	1,090	38,138	79,117	—	—
Convertible notes finance fee	—	−152,726	−104,245	—	—
Change in fair value of derivative liabilities	−74,406	555,789	2	94,025	—
Change in fair value of convertible notes	−3,351	122,553	—	—	—
Gain on sale of marketable securities	—	28,550	4,970	—	—
Gain on settlement of debt	342,650	—	—	328,687	—
Loss on settlement of convertible debt	—	−833,501	−477,221	—	—
Total other (expense) income	195,155	−1	−700,341	−474,170	590,858
Net loss	−12	−9	−7	−3	−1
Weighted average common shares outstanding - basic	2	114,807	2	10	9
Net loss per shares - basic	−7.16	−79.65	−3.53	−0.29	−0.12
Weighted average common shares outstanding - diluted	2	115,493	2	10	—
Net loss per share - diluted	−7.16	−82.6	−3.53	−0.29	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	334,005	2	3	8	504,749
Prepaid expenses and other current assets	168,906	290,773	—	—	—
Total current assets	502,911	2	6	9	509,615
Property and equipment, net	17,319	19,364	24,827	12,592	18,564
Intangible assets, net	10	—	—	—	—
Deferred financing costs	12,122	—	—	—	—
Operating lease right-of-use asset	102,383	276,009	333,904	56,122	116,982
Total Assets	10	3	6	9	651,641
Accounts payable and accrued expenses	1	596,600	—	—	—
Contingent consideration liability	2	—	—	—	—
Consideration payable	4	—	—	—	—
Accrued interest payable - related parties	—	1,785	—	—	—
Notes payable to related parties	—	190,270	—	—	—
Operating lease liability	77,194	60,909	52,479	62,823	66,934
Total current liabilities	8	2	1	975,676	2
Derivative liability	99,687	25,281	414,512	—	—
Operating lease liability non-current	154,953	238,088	304,127	—	62,442
Total Liabilities	8	2	2	975,676	2
Commitments and contingencies (Note 9)	—	—	—	—	—
Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding	—	—	—	—	—
Common stock, $0.00001 par value; 100,000,000 shares authorized; 2,023,615 shares issued and outstanding at December 31, 2025; 163,093 shares issued and outstanding at December 31, 2024	20	2	20	136	93
Additional paid in capital	49	35	29	17	—
Accumulated deficit	−46	−35	−25	−9	−6
Total Stockholders Equity	2	709,152	4	8	−2
Total Liabilities and Stockholders Equity	10	3	6	9	651,641

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	290,107	5,463	—	—	—
Amortization of debt discount and finance fees	62,030	1	2	885,505	3,389
Gain on settlement of debt	342,650	—	—	—	—
Accrued interest settled with common stock	—	54,670	294,927	—	—
Stock-based compensation	932,967	259,744	181,960	403,956	910,067
Expense for debt issuance costs due to fair value election on convertible notes	—	107,491	—	—	—
Expense for issuance costs due to liability classified warrants	—	28,477	—	—	—
Loss on issuance of convertible notes - fair value option	—	16,758	—	—	—
Impairment of right-of-use asset	109,235	—	—	—	—
Interest payments on convertible notes accounted for at fair value	−115,339	—	—	—	—
Accrued interest income	—	14,901	−14,901	—	—
Prepaid expenses	121,867	−176,300	46,675	−156,282	7,713
Accounts payable and accrued expenses	422,994	313,741	166,115	−382,881	—
Accounts payable and accrued expenses - related parties	—	−446	−12,054	12,500	—
Accrued interest payable	—	−15,056	110,453	−13,177	160
Accrued interest payable - related parties	−1,785	1,785	−98,135	51,188	—
Other assets	—	—	6,480	—	—
Change in operating lease asset and liabilities	−2,459	286	16,001	−5,693	−58,468
Net cash used in operating activities	−9	−7	−6	−3	−300,336
Investment in marketable securities	—	−43,587	−3	—	—
Proceeds from disposition of marketable securities	—	3	187,895	—	—
Payments made for capitalized software	−12,000	—	—	—	—
Investment in developed technology related to Molecule.ai Asset Acquisition	−3	—	—	—	—
Net cash (used in) provided by investing activities	−3	3	−3	—	—
Proceeds from note payable-related party	—	250,000	—	50,000	120,000
Repayment of note payable-related party	−190,270	−59,730	−685,473	−50,000	—
Proceeds from convertible notes payable	—	790,000	4	600,715	—
Proceeds from issuance of common stock, warrants and pre-funded warrants, net of placement agent fees of $504,770	—	4	—	10	—
Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of $322,501	5	—	—	—	—
Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of $170,000	4	—	—	—	—
Proceeds from issuance of pre-funded warrants, net of issuance costs of $235,514	2	—	—	—	—
Payment of other issuance costs for issuance of common stock and equity-classified warrants	−557,659	−235,707	—	—	—
Payment for issuance costs related to liability-classified warrants	—	−28,477	—	—	—
Proceeds from exercise of pre-funded warrants	20,151	729	—	—	—
Payment for finance costs	−74,152	−107,491	−345,000	—	—
Payment of convertible note payable	—	−846,806	—	—	—
Net cash provided by (used in) financing activities	11	4	3	11	687,932
Net change in cash and cash equivalents	−2	−656,272	−6	8	387,596
Interest	125,296	86,589	164,807	39,201	293
Income taxes	—	—	—	—	—
Conversion of convertible notes accounted for at at fair value	572,217	—	—	—	—
Issuance costs in accrued expenses	18,944	—	—	—	—
Asset acquisition costs in accounts payable and accrued expenses	72,582	—	—	—	—
Common stock issued for settlement of debt	—	2	3	588,524	—
Common stock issued for Molecule.ai Asset Acquisition	564,073	—	—	—	—
Consideration payable recognized in asset acquisition	4	—	—	—	—
Contingent consideration recognized in asset acquisition	2	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro